• Publications

    # These authors contributed equally

    ^ These authors contributed equally

    Bold Lab members


    Wang AZ, Mashimo BL#, Schaettler MO#, Sherpa ND, Leavitt LA, Livingstone AJ, Khan SM, Li M, Anzaldua-Campos M, Bradley JD, Leuthardt EC, Kim AH, Dowling JL, Chicoine MR, Jones PS, Choi BD, Cahill DP, Carter BS, Petti AA^, Johanns TM^, Dunn GP^. Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population [Internet]. bioRxiv. 2023 p. 2023.08.25.554678; Available from: https://www.biorxiv.org/content/10.1101/2023.08.25.554678v1


    Schaettler MO, Desai R, Wang AZ, Livingstone AJ, Kobayashi DK, Coxon AT, Bowman-Kirigin JA, Liu CJ, Li M, Bender DE, White MJ, Kranz DM, Johanns TM, Dunn GP. TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. J Immunother Cancer. 2023 Feb;11(2):e006121. doi: 10.1136/jitc-2022-006121. PMID: 36808076; PMCID: PMC9944319.


    Khan SM#, Desai R#, Coxon A, Livingstone A, Dunn GP, Petti A, Johanns TM. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors. J Immunother Cancer. 2022 Dec;10(12):e005293. doi: 10.1136/jitc-2022-005293. PMID: 36543376; PMCID: PMC9772691.


    Bowman-Kirigin JA, Desai R, Saunders BT, Wang AZ, Schaettler MO, Liu CJ, Livingstone AJ, Kobayashi DK, Durai V, Kretzer NM, Zipfel GJ, Leuthardt EC, Osbun JW, Chicoine MR, Kim AH, Murphy KM, Johanns TM, Zinselmeyer BH, Dunn GP. The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain. Cancer Immunol Res. 2023 Jan 3;11(1):20-37. doi: 10.1158/2326-6066.CIR-22-0098. PMID: 36409838.



    Wang AZ # , Bowman-Kirigin JA#, Desai R, Kang LI, Patel PR, Patel B, Khan SM, Bender D, Marlin MC, Liu J, Osbun JW, Leuthardt EC, Chicoine MR, Dacey RG Jr, Zipfel GJ, Kim AH, DeNardo DG, Petti AA^, Dunn GP^. Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. Genome Med. 2022 May 10;14(1):49. doi: 10.1186/s13073-022-01051-9. PMID: 35534852; PMCID: PMC9088131.


    Dunn GP, Sherpa N, Manyanga J, Johanns TM. Considerations for personalized neoantigen vaccination in Malignant glioma. Adv Drug Deliv Rev. 2022 Jul;186:114312. doi: 10.1016/j.addr.2022.114312. Epub 2022 Apr 26. PMID: 35487282.


    Schaettler MO#, Richters MM#, Wang AZ, Skidmore ZL, Fisk B, Miller KE, Vickery TL, Kim AH, Chicoine MR, Osbun JW, Leuthardt EC, Dowling JL, Zipfel GJ, Dacey RG, Lu HC, Johanns TM, Griffith OL, Mardis ER, Griffith M^, Dunn GP^. Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. Cancer Discov. 2022 Jan;12(1):154-171. doi: 10.1158/2159-8290.CD-21-0291. Epub 2021 Oct 5. PMID: 34610950.


    Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Semin Cancer Biol. 2022 Jan;78:63-77. doi: 10.1016/j.semcancer.2021.03.002. Epub 2021 Mar 9. PMID: 33711414.



    Bowman-Kirigin JA, Saunders BT, Desai R, Wang AZ, Schaettler MO, Liu CJ, Livingstone AJ, Kobayashi DK, Durai V, Kretzer NM, Zipfel GJ, Leuthardt EC, Osbun JW, Chicoine MR, Kim AH, Murphy KM, Johanns TM, Zinselmeyer BH, Dunn GP. The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain [Internet]. bioRxiv. 2021. p. 2021.09.13.460088. Available from: https://www.biorxiv.org/content/biorxiv/early/2021/09/15/2021.09.13.460088.


    Bender DE, Schaettler MO, Sheehan KC, Johanns TM, Dunn GP. Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms. Biomark Insights. 2021 Mar 30;16:11772719211006666. doi: 10.1177/11772719211006666. PMID: 33854293; PMCID: PMC8013708.


    Dunn GP, Bernstein B. Serving on the Navy's Hospital Ships During the Response to COVID-19: Perspective from Two Deployed Missouri Physicians. Mo Med. 2021 Mar-Apr;118(2):110-112. PMID: 33840845; PMCID: PMC8029620.


    Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 Oct 14;22(10):1425-1438. doi: 10.1093/neuonc/noaa154. PMID: 32615600; PMCID: PMC7686464.


    Liu CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, Kobayashi DK, Livingstone AJ, Bender D, Miller CA, Kranz DM, Johanns TM, Dunn GP. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro Oncol. 2020 Sep 29;22(9):1276-1288. doi: 10.1093/neuonc/noaa050. PMID: 32133512; PMCID: PMC7523441.


    Fu Y, Liu CJ, Kobayashi DK, Johanns TM, Bowman-Kirigin JA, Schaettler MO, Mao DD, Bender D, Kelley DG, Uppaluri R, Bi WL, Dunn IF, Tao Y, Luo J, Kim AH, Dunn GP. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Sci Rep. 2020 Jun 3;10(1):9027. doi: 10.1038/s41598-020-65915-z. PMID: 32493985; PMCID: PMC7271235.


    Patel B, Taiwo R, Kim AH, Dunn GP. TERT, a promoter of CNS malignancies. Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa025. doi: 10.1093/noajnl/vdaa025. Epub 2020 Feb 28. PMID: 32226942; PMCID: PMC7086299.


    Coxon AT, Johanns TM, Dunn GP. An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments. Mo Med. 2020 Jan-Feb;117(1):45-49. PMID: 32158049; PMCID: PMC7023938.


    Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, Campian JL, Chicoine MR, Dacey RG, Huang J, Fritsch EF, Gillanders WE, Artyomov MN, Mardis ER, Schreiber RD, Dunn GP. Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology. 2019 Jan 25;8(4):e1561106. doi: 10.1080/2162402X.2018.1561106. PMID: 30906654; PMCID: PMC6422384.


    Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP. Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. Neurosurgery. 2017 Sep 1;64(CN_suppl_1):165-176. doi: 10.1093/neuros/nyx321. PMID: 28899059; PMCID: PMC6287409.


    Johanns TM, Dunn GP. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. Cancer J. 2017 Mar/Apr;23(2):125-130. doi: 10.1097/PPO.0000000000000247. PMID: 28410300; PMCID: PMC5605294.



    Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunol Res. 2016 Dec;4(12):1007-1015. doi: 10.1158/2326-6066.CIR-16-0156. Epub 2016 Oct 31. PMID: 27799140; PMCID: PMC5215735.


    Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 2016 Nov;6(11):1230-1236. doi: 10.1158/2159-8290.CD-16-0575. Epub 2016 Sep 28. PMID: 27683556; PMCID: PMC5140283.


    Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP. High incidence of TERT mutation in brain tumor cell lines. Brain Tumor Pathol. 2016 Jul;33(3):222-7. doi: 10.1007/s10014-016-0257-5. Epub 2016 Mar 9. PMID: 26960334; PMCID: PMC5605295.